[
    [
        {
            "time": "2021-06-03",
            "original_text": "药明康德(02359)共有239.04万份股票期权达成行权条件",
            "features": {
                "keywords": [
                    "药明康德",
                    "股票期权",
                    "行权条件"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)共有239.04万份股票期权达成行权条件",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "突破进口垄断 纳微科技计划科创板上市",
            "features": {
                "keywords": [
                    "纳微科技",
                    "科创板",
                    "进口垄断"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "突破进口垄断 纳微科技计划科创板上市",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "浙商证券：5月金股组合盈利5.66% 6月荐股名单出炉",
            "features": {
                "keywords": [
                    "浙商证券",
                    "金股组合",
                    "荐股名单"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券：5月金股组合盈利5.66% 6月荐股名单出炉",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "兴业证券：5月金股组合盈利5.83% 6月荐股名单出炉",
            "features": {
                "keywords": [
                    "兴业证券",
                    "金股组合",
                    "荐股名单"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "兴业证券：5月金股组合盈利5.83% 6月荐股名单出炉",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "融资丨「斯微生物」完成近2亿美元新一轮融资，招商健康、红杉资本中国基金、景林投资、药明康德共同领投",
            "features": {
                "keywords": [
                    "斯微生物",
                    "融资",
                    "红杉资本",
                    "药明康德"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "融资丨「斯微生物」完成近2亿美元新一轮融资，招商健康、红杉资本中国基金、景林投资、药明康德共同领投",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "国信证券：医药板块调整后延续反弹态势，回归均衡风格",
            "features": {
                "keywords": [
                    "国信证券",
                    "医药板块",
                    "调整",
                    "反弹"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国信证券：医药板块调整后延续反弹态势，回归均衡风格",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "医药生物2021年6月策略：不忘疫情防控，重视创新与消费升级",
            "features": {
                "keywords": [
                    "医药生物",
                    "疫情防控",
                    "创新",
                    "消费升级"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物2021年6月策略：不忘疫情防控，重视创新与消费升级",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-06-03",
            "original_text": "纳微科技：解决卡脖子材料替代，迎来中国生物药爆发增长机遇",
            "features": {
                "keywords": [
                    "纳微科技",
                    "卡脖子材料",
                    "生物药",
                    "增长机遇"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "纳微科技：解决卡脖子材料替代，迎来中国生物药爆发增长机遇",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]